Caris Life Sciences, Inc. Common Stock (CAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has a cash flow conversion efficiency ratio of 0.055x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($32.88 Million) by net assets ($593.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CAI cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Caris Life Sciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Caris Life Sciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turkcell Iletisim Hizmetleri A.S
F:TUL1
|
0.103x |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
-0.003x |
|
OHB SE
XETRA:OHB
|
-0.052x |
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
-0.035x |
|
Hedef Holdings AS
IS:HEDEF
|
0.025x |
|
CSPC Innovation Pharmaceutical Co Ltd Class A
SHE:300765
|
-0.010x |
|
UNIQA Insurance Group AG
VI:UQA
|
0.072x |
|
Ningbo Ginlong Technologies Co Ltd Class A
SHE:300763
|
0.098x |
Annual Cash Flow Conversion Efficiency for Caris Life Sciences, Inc. Common Stock (2005–2025)
The table below shows the annual cash flow conversion efficiency of Caris Life Sciences, Inc. Common Stock from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Caris Life Sciences, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $577.31 Million | $83.16 Million | 0.144x | +46.79% |
| 2024-12-31 | $-2.50 Billion | $-245.20 Million | 0.098x | -23.77% |
| 2023-12-31 | $-2.14 Billion | $-276.10 Million | 0.129x | -23.31% |
| 2022-12-31 | $-1.70 Billion | $-285.71 Million | 0.168x | -57.45% |
| 2020-12-31 | $702.24 Million | $277.02 Million | 0.394x | +7.66% |
| 2019-12-31 | $693.24 Million | $254.00 Million | 0.366x | +42.90% |
| 2018-12-31 | $701.13 Million | $179.77 Million | 0.256x | -6.84% |
| 2017-12-31 | $563.85 Million | $155.19 Million | 0.275x | -2.58% |
| 2016-12-31 | $457.50 Million | $129.26 Million | 0.283x | -11.57% |
| 2015-12-31 | $461.26 Million | $147.37 Million | 0.319x | +1.30% |
| 2014-12-31 | $442.90 Million | $139.69 Million | 0.315x | +5.43% |
| 2013-12-31 | $415.13 Million | $124.19 Million | 0.299x | -2.87% |
| 2012-12-31 | $346.85 Million | $106.83 Million | 0.308x | +6.25% |
| 2011-12-31 | $248.74 Million | $72.11 Million | 0.290x | +35.07% |
| 2010-12-31 | $197.67 Million | $42.42 Million | 0.215x | -10.04% |
| 2009-12-31 | $129.10 Million | $30.80 Million | 0.239x | -1.06% |
| 2008-12-31 | $113.79 Million | $27.44 Million | 0.241x | +11988.54% |
| 2007-12-31 | $131.15 Million | $-266.00K | -0.002x | -100.67% |
| 2006-12-31 | $27.75 Million | $8.38 Million | 0.302x | -66.15% |
| 2005-12-31 | $32.99 Million | $29.41 Million | 0.891x | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more